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Abstract 
Hybrid iron oxide-gold nanoparticles (HNPs) are capable of drug binding onto their surface 
with a triggered release at elevated temperatures. The iron oxide core allows for diagnostic 
imaging whilst heating of the gold shell upon laser irradiation reverses drug binding. This 
study exploits the reversible binding of novel polyamine based drugs in order to provide 
specific and effective method for pancreatic cancer treatment. Here we used novel 
bisnaphthalamido (BNIP) based drug series. Our hybrid nanoparticles (50 nm) were capable 
of drug loading onto their surface (3:1:0.25, Drug:Fe:Au). By exploiting the surface-to-drug 
electrostatic interaction of a range of BNIP agents, heat triggered drug release was achieved. 
12-fold reduction in IC50 after 24 h in vitro and 5-fold reduction of tumour retardation in vivo 
compared with free drug in pancreatic models after treatment with the HNP-formulation and 
laser irradiation. This heat activated system could provide a key platform for future therapy 
strategies. 
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1. Introduction 
Pancreatic cancer is the 4th most aggressive cancer in the western world [1]. Unfortunately, no 
major advancement in patient diagnosis, treatment or prognosis has been made in the last 40 
years. Thus the number of deaths from this disease is set to rise approximately 28% by 2026 
[2]. Treatment of this disease is often hindered by lack of symptoms, late diagnosis and the 
lag time between diagnosis, referral and treatment. Of those patients diagnosed with 
pancreatic cancer approximately 80% will die within a year of diagnosis and only 3% will 
survive 5 years [2]. In order to treat this devastating disease new technologies which 
overcome the major barriers to treatment must be developed. Currently the first line 
chemotherapy for pancreatic cancer is nucleoside analogue, gemcitabine. However, 
gemcitabine only proves effective in 23.8 % of patients [3]. It is thought this is due to a dense 
stroma which surrounds the tumours and hampers drug penetration [4]. One strategy that has 
shown promise to increase drug penetration and increase efficiency of treatments is to couple 
chemotherapies onto nanoparticle carriers [5-10]. Nanoparticulates possess the ability to be 
either passively targeted to tumour vasculature through the enhanced permeability and 
retention effect [11] or actively targeted to specific sites after functionalisation with specific 
ligands [12]. Previous studies have shown that after coupling cytotoxics onto nanoparticles, 
this increased tumour penetration and resulted in more effective therapies [13-16].  
 
Iron oxide-gold hybrid nanoparticles (HNPs) have recently been the focus of a number of 
investigations and are becoming increasingly applicable in biomedicine [17-20]. By using 
iron oxide (Fe3O4) and elemental gold (Au) within one platform, a multifunctional and stable 
system can be fabricated [21,22]. This exploits the surface chemistry and heating potential 
resulting from laser irradiation at the surface plasmon resonance (SPR) of the gold coating 
and the magnetic character of the iron oxide core, offering potential as an image guided drug 
carrier or theranostic agent. Reports using HNPs for delivery of anticancer agents have 
attached chemotherapies onto the gold surface via linker moieties or exploitation of sulfur-
gold chemistry [22,23].  
 
In this study drug attachment onto the gold surface of HNPs via electrostatic interaction is 
explored for the first time as a potential loading and release strategy. Electrostatic interactions 
with polymers or stabilising agents are commonly used for functionalisation of nanoparticles 
but, to the best of our knowledge, have not been reported as a mechanism for stimuli 
responsive drug delivery from HNPs. Stimuli responsive drug delivery occurs when drug 
release is initiated by a change in environmental conditions, such as temperature or pH. The 
rationale is that positively charged drug molecules will form electrostatic interactions with 
the overall negatively charged gold surface of the HNPs. Electrostatic bonds are charge-
charge interactions which may be cleaved at increased temperatures when the energy 
threshold required to break these bonds is reached [24]. Here we exploit the nano-heating 
properties of these HNPs in order to break the electrostatic binding of drug molecules which 
results in localised triggered drug release (Fig. 1A). This reversible binding mechanism 
allows for controllable release of pharmaceutical agents in their parent state unhindered by 
addition of linkers or permanent bonds, hence no reduction in drug activity is experienced as 
is so commonly observed in controlled release systems [25].  
 
Here a series of novel bisnaphthalimide drug analogues with a chain of 20 atoms separating 
two naphthalimido residues will be used (Fig. 1B). Brana et al. reported bisnaphthalimides as 
potent chemotherapeutic agents [26-29]. Bisnaphthalimide derivatives are identified to 
possess significant anti-tumour activity in both murine and human cancerous cells [26-29]. 
Due to the presence of planar aromatic moieties, these molecules can intercalate within the 
DNA by entry via the major groove [30]. Hoskins et al. showed that the potency of an 
insoluble bisnaphthalimido compound could be enhanced in vitro and in vivo in pancreatic 
models using a nano-aggregate of poly(allylamine) modified with cholesteryl chains. This 
aggregate increased drug solubilisation and resulted in more rapid drug uptake into pancreatic 
cancer BxPC-3 cells compared with the free drug. A similar clinical effect was experienced 
with the clinically used drug gemcitabine at 8-fold less dose [31].  
 
In this study, a number of soluble bisnaphthalamide analogues with a backbone containing 
different number of charged amino residues were electrostatically conjugated onto the HNP 
surface (Fig. 1A). In order to determine the effect of drug charge on the loading concentration 
and subsequent drug release, we used bisnaphthalimido: 1,20 diaminoicosane (BNIPDi) 
(containing no amino residues), 1,12 diaminooctane dihydrogen bromide (BNIPd), propyl 
spermine tetrahydropbromide (BNIPSpm), and propyl 3,3’-butane-1,4-
diylbis(sulfanediyl)bis(propan-1-amine) (BNIPds) (Fig. 1B). The temperature dependant 
release and biological activity of the novel systems was evaluated both in vitro and in vivo in 
order to ascertain clinical relevance of these systems for pancreatic cancer therapy. 
 
 
2. Experimental 
All chemicals and solvents used were commercially available and purchased from Sigma 
Aldrich (UK) unless otherwise stated. Anhydrous solvents were purchased as such or dried 
using standard techniques. Cell culture media was purchased from Thermofisher (UK). All 
cell lines used were purchased from ATCC, LGC Standards UK and mice were purchased 
from Charles River, UK. 
 
2.1 Synthesis and characterisation of drug molecules 
The drug compounds were synthesised according to the methodology outlines in the 
Supplementary Information (SI-Methods 1.0). The drugs were characterised using 1H, 13C 
and 19F NMR spectra which were recorded at 300 MHz using a Bruker Spectrospin DPX 300 
Spectrometer and at 400 MHz using a Bruker Ascend 400 spectrometers; Multiplicities were 
recorded as broad peaks (br), singlets (s), doublets (d), triplets (t), quartets (q), quintets (qu), 
double doublets (dd), and multiplets (m). All NMR samples were made up in deuterated 
solvents with all values quoted in ppm relative to tetramethylsilane (TMS) as an internal 
reference. Coupling constants (J values) are reported in Hertz (Hz). High resolution mass 
spectrometry analyses were performed using a ThermoFisher Scientific LTQ Orbitrap XL 
hybrid ion trap-orbitrap mass spectrometer. Samples were introduced to the spectrometer as 
solutions in dichloromethane/methanol with ammonium acetate added. All compounds 
analysed gave satisfactory data at high resolution as compared to predicted ionisation 
patterns.  
 
2.2 HNP - drug conjugation and characterisation 
HNP-Drug conjugation: To a solution of HNPs (1 mgmL-1, 5 mL) a 5 mg, 12.5 mg or 25 mg 
of drug was added along with 25 mg of poly(ethylene glycol) thiol. The solution was stirred 
for 3 h at 25 ˚C.  The particles were magnetically separated and extensively washed with 
deionised water.  
 
Drug attachment was quantified by reverse phase high performance liquid chromatography 
(HPLC) (Prominence, DEGASSER, LC20AD, SHIMADZU) using a fluorescent detector at 
excitation 234 nm and emission 394 wavelengths (Jasco, PU-980, Japan; column C18(2), 
150×4.60 mm 5 micron, flow rate 1mL/min, injection volume 20 µL). A buffer was prepared 
by adding 0.432 g octane sulfonic acid and 1.64g sodium acetate to 200 mL of deionised 
water. Then the pH of the solution was reduced to pH 4.5 by the addition of hydrochloric 
acid. Mobile phase was prepared by mixing buffer and acetonitrile with the percentage of 
70% and 30%, respectively. A flow rate of 1 mL min-1 was employed. A calibration was run 
using drug solutions dissolved in 50:50 H2O: Aceotnitrile with the concentration of 100-1.56 
µgmL-1 (R2 = 0.9999). All measurements were run in triplicate and recorded as average 
values.  
 
Formulations with the highest drug loading concentrations (5 mL) were freeze dried using a 
Heto PowerDry LL3000, Thermo-Fisher UK. The freeze dried samples were analysed by 
FTIR spectroscopy using a diamond tipped attenuated total reflectance attachment (Nicolette 
iS5 with iD5 ATR, Thermo-Fisher UK) at resolution of 4 cm-1 and 64 scans were run at room 
temperature with background subtraction in order to qualitatively verify drug presence. 
 
Aqueous formulations were characterised at room temperature on the Luminescence 
Spectrometer (Varian, Cary Eclipse Fluorescence Spectrophotometer, USA) with excitation 
wavelength set at 234 nm. The samples were scanned for emission between 200 - 600 nm at 
400 nmsec-1, and the spectra were collected and analysed by the provided software. This 
software controls all aspects of the system, such as control of the slits at the entrance and exit 
ports of the spectrograph, detector gain, blank-subtraction, system correction files and 
automated batch-processing. 
 
Zeta potential measurements were carried out using a photon correlation spectrometer (PCS, 
Zetasizer Nano-ZS, Malvern Instruments, UK). Samples were diluted in deionised water to 
make 1 mgmL-1
 
of HNPs and sonicated for 30 s before measuring the surface charge of the 
particles at 25 °C.  
 
Photon correlation spectroscopy (PCS) carried out in order to evaluate particle size before 
and after drug conjugation. Samples were analysed at 25 °C using a PCS, Zetasizer Nano-ZS, 
Malvern Instruments, UK). Samples were run in triplicate and an average value recorded. 
Additional size measurements were carried out using transmission electron microscopy 
(TEM). TEM imaging was carried out using the JEOL JEM-1230 (JEOL, Japan) transmission 
electron microscope. Prior to imaging, formvar coated copper grids were prepared. The 
samples were pipetted (10 µL) onto the grids and allowed to air dry before imaging. Sample 
diameter was measured and recorded for 20 particles and an average size recorded. 
 
2.3 Stability of HNP-drug formulations 
The formulations were tested as both aqueous solutions and dried formulations. These studies 
was run at both room temperature and 4 ˚C over the period of 4 weeks. For the aqueous 
formulations, 1 mL of each formulation (drug concentration = 0.5 mgmL-1) was kept at room 
temperature and 4 ˚C and the supernatant was analysed each week with HPLC. For studying 
the stability of powder formulations 1 mL of each formulation with the same mentioned 
concentration was freeze dried. Each week samples were reconstituted in deionised water and 
the concentration of released drug investigated via HPLC as previously described. All 
measurements were run in triplicate and recorded as average values. 
 
2.4 In vitro drug release 
Formulations (2 mL, 500 µgmL-1) were placed into visking tubing (12-14 KDa) and dialysed 
against 200 mL deionised water / cell culture media (RPMI, pH adjusted to 7.4, 4.6 & 3.6) at 
(20 ˚C, 30 ˚C, 40 ˚C, 44 ˚C, 50 ˚C & 60 ˚C). At selected time points (0.083 h, 0.17 h, 0.33 h, 
0.5 h, 1 h, 4 h, 6 h, 8 h, 24 h, 48 h, 72 h, 144, 168 and 216 h) a sample of the exterior solution 
(1 mL) was removed and replaced with 1 mL deionised water at the specified time points. All 
samples were diluted with 1 mL of acetonitrile and drug concentrations were analysed via 
HPLC as previously described. The experiment was carried out in triplicate and the peak area 
compared to a calibration of the free drug dissolved in acetonitrile/H2O (50:50) (R2= 0.999). 
 
2.5 In vitro evaluation 
Human pancreatic adenocarcinoma (BxPC-3), human epithelial ductal carcinoma (PANC-1) 
and human myeloid monocyte (U937) cells were cultured in RPMI (BxPC-3 & U937) AND 
DMEM (Panc-1) media. The media was supplemented with 1 % penicillin/streptomycin and 
10 % foetal bovine serum (1 % of L-glutamine was also added to PANC-1 & U937 media). 
U937 cells were differentiated with 0.02 % of phorbol-12-myristate 13-acetate (PMA) (50 
µgmL-1 in PBS) was added to the cells suspension in order to transform them into 
macrophage like cells before testing. 
 
2.5.1 MTT Assay 
Cells (100 µL, 15000 cells/well) in exponential growth phase were seeded into 96 well flat 
bottomed plates and incubated for 24 h at 37 °C with 5 % CO2. After 24 h, the media was 
replaced with various concentrations of gemcitabine, free bisnaphthalamide based drugs, 
naked HNPs and novel formulations, diluted in cellular growth medium (0.01 µgmL-1
 
- 500  
µgmL-1). After 24 h, the drug solutions were removed and washed with fresh media. 3-[4, 5-
dimethylthiazole-2-yl]-2, 5-diphenyl tetrazolium (MTT, 50 µL, 5 mgmL-1
 
in PBS) was added 
to the wells and plate was incubated (37 °C with 5 % CO2) for 4 h. After this time, the MTT 
solution was removed from the wells. The remaining purple formazan complexes were 
dissolved in DMSO (100 µL) and the absorbance of the plates was read at 570 nm using a 
microplate reader (Tecan, infinite 200 pro, GmbH 5082, Australia). Percentage cell viability 
and IC50 was calculated relative to positive and negative controls. 
 
2.5.2 Trypan blue cytotoxicity test  
Cells (1 mL, 50000 cells/well) were seeded into 12-well flat bottomed plates and incubated 
for 24 h at 37 °C with 5 % CO2. The media was replaced with drugs, HNPs and novel 
formulations at various concentrations (0.01 µgmL-1
 
- 500  µgmL-1). Cells were incubated for 
24 h, subsequently the media was removed and cells were washed 3 times with PBS. The 
cells were trypsinised and re-suspended in fresh media. A mixture of 50 µL of cells and 50 
µL of trypan blue solution was placed in an automated cell counter (Invitrogen CountessÒ, 
UK) and viable cells were counted. Percentage cell viability and IC50 were calculated in 
relation to control cells. 
 
2.5.3 Cellular uptake of formulations  
Cells (3 mL, 150000 cells/ well) were seeded into 6-well plates and incubated for 24 h at 
37°C with 5 % CO2. The media was replaced with 50 µgmL-1 and 100 µgmL-1
 
of different 
bisnaphthalamide based drugs, their hybrid formulations and gemcitabine and incubated for 1 
h and 4 h. The medium was removed and each well was washed with 1 mL PBS before the 
addition of 185 µL trypsin into each well. Cells re-suspended in 1 mL media and viable cells 
were counted using an automated cell counter (Invitrogen CountessÒ, UK). Cells (100,000) 
were transferred into eppendorf tubes and centrifuged (800 rpm, 5 min). The supernatant was 
removed and cells were resuspended in DMSO:water (1:1) (for samples containing 
bisnaphthalamide derivatives) or water (for samples containing gemcitabine). The drug 
concentration was quantified using reverse phase HPLC. Analysis of the bisnaphthalimides 
was carried out via HPLC as described in the drug loading methodology. Gemcitabine 
quantification was carried out using an HPLC instrument with UV detector (Perkin Elmer, 
Flexar Autosampler, column: SPHERISORB ODS 2 5µm, length 250 mm, internal diameter 
4.6 mm) and a mobile phase of water:acetonitrile (30:70). The samples were detected at 234 
nm with flow rate of 1 mL.  
 
2.5.4 Thermo-responsive cytotoxicity  
Cells (3 mL, 150000 cells/well) in their exponential growth phase were seeded into 6-well 
plates and incubated for 24 h at 37 °C with 5 % CO2. Cells were treated with 50 µgmL-1
 
of 
drugs and formulations and incubated for 1 h. Then, cells were further incubated at 25 °C, 44 
VC and 60 °C for 0.5 h, in order to investigate the effect of temperature on cell cytotoxicity. 
Then the drug solutions were removed and cells were washed with fresh media to remove any 
excess drug. Fresh media was then added to each well. After 24 h incubation (37 °C, 5 % 
CO2), media was removed and cells were washed with PBS. The cells were counted using 
trypan blue exclusion as described above.  
 
2.5.5 AFM topography imaging  
Cells (3 mL, 150000 cells/well) were seeded in 6-well plates containing glass coverslips and 
incubated for 24 h at 37 °C and 5 % CO2. After 24h the media was replaced with 
gemcitabine, BNIPSpm, HNP-BNIPSpm and naked HNPs solution (50 µgmL-1) and further 
incubated for 1 h and 4 h. After abundant washing with PBS, cells were fixed with 1 mL 
gluteraldehyde (2.5 % in PBS) for 10 min. Fixed cells were washed 5 times with PBS and 
mounted on glass slides. Cell topography was imaged with a Bruker Catalyst Atomic Force 
Microscope (Bruker, Germany) using ScanAsyst mode in air (using silicon tip (Bruker, T: 
650 nm, L: 115 µm, W: 25 µm) on nitride lever).  
 
2.6 In vivo evaluation  
Female Nu/Nu mice, 5 weeks of age (Charles River, UK) were kept in pathogen-free 
conditions (weight of mice was 20–25 g). All procedures and animal care were carried out 
according to Project License PPL 70/8806 granted by the UK Home Office. Human 
pancreatic cancer cell line BxPC-3 was cultured to 90 % confluence in RPMI 1640 
supplemented with 10 % fetal bovine serum and 1 % penicillin streptomycin. The cells were 
washed twice with cold PBS and harvested with trypsin for 10 min at 37 °C. The cells were 
washed three times with PBS and resuspended in 50:50 media:PBS. The tumour cell 
suspension (3.0 X 106 cells in 100 µL) was injected subcutaneously (s.c.) in the right flank of 
each mouse. When the tumour became palpable (approximately after one week), 
measurements in two dimensions with vernier calipers were carried out twice a week and 
volume tumours calculated according to equation (1).  
V = 4/3π[(D1 + D2)/4]3    (1) 
Once tumours had reached 0.1 cm3 therapeutic studies commenced. The mice were grouped 
into 8 arms (n=5) of control, HNP, BNIPSpm, HNP-BNIPSpm all with and without laser 
irradiation. Drug administration was 3 mgKg-1 with equivalent HNP concentration used in the 
HNP control. Doses were injected intratumorally (I.T.) using a 26 gauge needle (Vet-Tech, 
UK) at a maximum of 100 µL. The dose was administered one dose per week over a four 
week period. Where laser irradiation was required this was carried out 24 h after dosing under 
anaesthetic. The tumour was irradiated at 1064 nm for 20 sec using a ML-LASER-YB5 Q-
switched Nd:YAG Laser Treatment System (WeiFang MingLiang Electronics Company Ltd., 
China). Pulse width: 10 ns, pulse repetition frequency: 6 Hz, laser spot diameter: 3 mm, 
cooling system: water cooled with airflow cooling. The beam was collimated through 
concave lenses to a 1 mm diameter. Any mouse whose tumour volume reached 0.9 cm3 was 
sacrificed in line with good practice guidelines [32].  
2.7Statistical analysis 
A simple two tailed t-test was carried out in excel to determine the statistical significance of 
results, whereby p£0.01 was significant. 
 
3. Results and Discussion 
3.1 Synthesis and characterisation of drug molecules 
The drug molecules used in this study were synthesized using established methodology 
according to the general scheme shown in Fig. 2 [33]. The identity of these compounds was 
confirmed by NMR spectroscopy and Mass spectrometry (SI-Fig. 1). 
 
3.2 HNP-Drug conjugation and characterisation 
The HNP preparation and characterisation has been reported previously [21,22] along with 
their ability to undergo triggered heating upon laser irradiation in agar phantoms [17,34], in 
vitro and in situ in tumour bearing mouse cadavers [35,36]. Drug attachment was carried out 
at three drug:HNP weight ratios (5:1, 2.5:1 and 1:1 based on Fe weight of HNP) for all four 
bisnaphthalamide based drugs. Higher initial drug weight concentrations were not 
investigated due to the lack of aqueous solubility of the drug analogues over 5 mgmL-1. The 
data suggested that BNIPDi could not be conjugated onto the surface of HNPs due to the lack 
of protonated amino group (Fig. 3A), which is essential for electrostatic interaction, or any 
other driving force for conjugation. FTIR spectral analysis (SI-Fig.2A), fluorescence 
spectroscopy (SI-Fig.3A) and the lack of shift in zeta potential measurement of the BNIPDi 
formulations (Fig. 3B) confirmed that no drug attachment had occurred. As a result, it was 
decided not to study these formulations further. Photon correlation spectroscopy (SI-Table 1) 
was inconclusive in terms of nanoparticle size. This was due to the fact that aggregation was 
occurring on measurement, particularly in the HNP with no drug coating. Indeed the 
measurements appeared to become more realistic after drug conjugation , this is likely to be 
due to the stabilizing effect of the drug on the HNPs in solution, hence reducing their 
tendency to aggregate in solution. Size measured via TEM showed that there was no notable 
increase in particle size after drug conjugation onto the surface of the HNPs.  
 
Drugs with amino groups within their backbone did successful achieve binding onto the gold 
surface (Fig. 3A) in agreement with Aslam et al., who reported that gold has a strong affinity 
towards amino groups [37]. The successful binding between BNIPd and the HNP is due to 
electrostatic interaction between the two positively charged amino groups within this drug 
and the gold coating, as observed by the appearance of the N-H (700-800 cm-1), C=O (1658 
cm-1) and CH2 (2915 cm-1) stretching vibrations in the FTIR spectrum (SI-Fig.2B). 
Additionally, the zeta potential measurement showed a shift from -4 mV to +26 mV 
indicating the presence of amines. The presence of fluorescent emission at 424 nm further 
substantiated this (SI-Fig.3B). The loading pattern of BNIPd onto the HNP did not follow a 
linear relationship. In fact, after 2.5:1 drug:HNP loading the graph plateaued (Fig. 3A) 
suggesting weak electrostatic interactions being formed and broken due to competition of 
drug molecules for space on the HNP surface with surface saturation not being achieved. 
 
For BNIPSpm, increasing drug loading concentration resulted in greater drug attachment onto 
the nanoparticle surface (Fig. 3A). This could be due to the number of protonated amino 
groups present in the drug backbone (four in the case of BNIPSpm when compared to two in 
BNIPd), resulting in stronger electrostatic interactions between the drug and HNP. The 
absence of a plateau in the graph suggests that further conjugation could be possible and the 
HNP surface was not saturated; however, the physicochemical properties of the drug in 
solution hindered further attachment. BNIPSpm loaded onto the HNPs exhibited a linear 
correlation between the drug concentration solution fed to the particles and the attached drug 
concentration. For example our data showed that 5 mgmL-1 of loading BNIPSpm solution 
conjugated to the surface of HNPs at higher concentration compared to the other drugs 
investigated in this study. Approximately 3.4 mgmL-1 of BNIPSpm from the initial 5 mgmL-1 
loading concentrations was attached to the HNP, hence achieving a binding efficiency of 
68%. A shift in zeta potential was observed (Fig. 3B) which correlated well with the 
fluorescence and FTIR data (SI-Fig.2C & 3C), confirming the presence of drug on the HNP 
surface. 
 
BNIPds is conjugated to the HNP by dative covalent bonding of the sulfide residues with the 
Au surface. Au–S bonds are relatively strong, approximately 40 kcal mol−1 [38], compared 
with weaker Van der Waals forces. For BNIPds the graph did plateau at higher drug ratios 
(Fig. 3A) suggesting the particle surface was saturated and no more attachment was possible. 
Given the nature of the strong sulfide interaction achieved with BNIPds in addition to the 
electrostatic binding opportunities arising from the two amino groups, when compared with 
the potential for only electrostatic interactions of the other drugs investigated it is postulated 
that a more rigid binding occurs for BNIPds with less molecular flexibility, utilising greater 
surface area and hence leading to lower binding saturation concentrations. The reduced drug 
conjugation at the HNP surface was confirmed by a shift in the zeta potential measurement 
from -4 mV to + 10 mV. The presence of electronegative sulfur atoms in BNIPds may have 
contributed to the reduced zeta potential shift when compared to BNIPSpm and BNIPdi.  
 
Previous studies have shown that doxorubicin can be absorbed onto colloidal gold surfaces 
and electrostatically attached. In the case of this drugs, it has been shown that the 
hydrophobic moieties within the structure drive the molecule towards the gold surface and 
secondly the charge within the compound resulting from the one primary amine allow for 
electrostatic attachment [39]. The mechanism of bisnaphtalamide drug attachment onto the 
HNP surface may undergo a similar mechanistic approach to attachment, however, the 
multiple amine charges resulting from the polyamine chain far outweigh the hydrophobicity 
of the naphthalamide moieties within the drug structure resulting in a freely soluble drug 
compound, unlike in the case of doxorubicin. Hence, the mechanism in this case may solely 
rely on charge-charge interaction, without the initial push from the hydrophobic aromatic 
groups. More work is required in order to confirm the exact mechanism of the electrostatic 
interactions obtained for these drugs. 
 
 
3.3 Stability of HNP-drug formulations 
Stability studies of the drug-HNP formulations (Fig. 3C&D), including reconstituted freeze-
dried samples, were carried out in aqueous solution at 4 ˚C and room temperature (25 ˚C). 
These results showed that BNIPds did not dissociate from the HNP surface, which was 
expected due to the covalent linkage between sulfide and the Au surface of the HNP. BNIPd 
became almost totally unattached from the HNPs at both 4 ˚C and 20 ˚C probably due to the 
weak electrostatic interaction being broken down. BNIPSpm however, remained in 
formulation with more than 80 % of drug remaining attached to the HNPs in solution over the 
duration of the study. This is probably due to the increased number of charges in the drug 
resulting in a greater electrostatic force and tighter binding. The freeze-dried formulations 
were optimal with increased longevity observed. 
 
3.4 In vitro drug release 
Drug release was carried out under ‘sink’ conditions in aqueous solution (Fig. 4A) and in cell 
culture media with pH adjusted to mimic in vivo conditions (Fig. 4B). Studies with BNIPd 
showed that 100 % of the drug was released rapidly at 20 ˚C (almost 80 % after 0.5 h) (SI-
Fig.4); it is proposed that the charge-charge interaction is not strong enough for long-term 
stability of the formulation. Such instability and rapid dissociation from the formulation 
renders it unsuitable as a delivery system for this drug. In general, the BNIPSpm release from 
formulations in both water and culture media showed biphasic patterns, which include a sharp 
release in the first 10 h followed by a gradual release for the remainder of the experiment. 
Less than 10 % of drug had been released at a biologically relevant temperature i.e. 37 oC. At 
60 ˚C higher drug release occurred, after only 0.5 h almost 40 % of drug had been released 
from the formulations, which may also be achievable upon irradiation of the HNPs at the SPR 
over short time durations without detriment to surrounding cells. The release profiles of 
BNIPSpm formulations indicate that they are superior to the BNIPd formulations. It is 
hypothesized that the increased number of charged residues in BNIPSpm results in stronger 
electrostatic interactions which requires a larger input of energy to dissociate it from the HNP 
surface, thus the formulation is more stable at lower temperatures and only releases drug after 
heat stimulation.  
 
In our study BNIPSpm drug release in culture media at biologically relevant 
temperatures (37 ˚C) and pH (7.4) followed the same pattern of drug release seen in 
water, whereby increasing the temperature (from 37 ˚C to 44 ˚C) enhanced the drug 
release rate. A decrease in pH to intracellular levels resulted in further drug release. At 
pH 3.6, there was a significant increase in drug released from BNIPSpm-HNP 
compared to physiological pH. Thus, BNIPSpm-HNP formulations exhibited pH and 
thermo-responsive drug delivery properties. Therefore, it is envisaged that after 
accumulation of the HNPs inside the endosomes or lysosomes together with the low 
environmental pH accompanied by heating through laser irradiation will result in rapid 
drug release from the nanoparticles. Thus, allowing free drug to enter the nucleus to 
interact with DNA for therapeutic effect. As expected, due to the robust binding 
interaction of BNIPds, less than 2 % of the drug was released after 72 h at 60 ˚C (SI-
Fig.4). Therefore, BNIPds formulations cannot be utilised for thermally triggered drug 
delivery.  
 
Based on the above results, only BNIPSpm formulation studies were carried forward 
for in vitro and in vivo testing on pancreatic cancer cells. 
 
3.5 In vitro evaluation  
Cell viability of BxPC-3, Panc-1 and U937 cells exposed to HNP-BNIPSpm was 
determined using both the MTT assay and trypan blue exclusion (Fig. 5A). BxPC-3 
and Panc-1 cell lines were chosen in this study in order to gain realistic information on 
the potential of the formulations in pancreatic therapy. Cancer is not defined as one 
cell type, indeed it is a cellular mutation which leads to rapid proliferation, this can 
occur in multiple cell types within one cancer, which may react differently to 
treatment. Therefore, looking at more than one cell line may give more meaningful 
information and correlation between cellular response and in vivo outcome. In this 
study, generally, both cytotoxicity assays exhibited comparable results in the 
pancreatic cell lines. The naked HNPs did not present a remarkable dose response 
effect on cell viability up to 50 µgmL-1 (p>0.05) (SI-Fig.5). However, after 24 h incubation 
with the highest concentration of HNPs (100 µgmL-1) a 19-23% decrease in viability was 
obtained (p<0.05). As with any drug delivery vehicle, inherent toxicity is not desirable. In 
this case it is not a concern since the concentrations tested are more potent than would be 
expected to be administered in the drug formulation to a patient in the clinic. Over the 
concentration ranges and time points tested there was no IC50 evident for either the 
HNP (SI-Fig.4A) or gemcitabine (SI-Fig.4B). As gemcitabine is the gold standard for 
clinical treatment it was interesting to note that for BNIPSpm, after only 24 h an IC50 
value was detected, hence this indicates that the novel drug is more rapid and 
potentially more toxic than the clinical gold standard.  
 
Consistently in the pancreatic cancer cell lines (BxPC-3 and Panc-1), when BNIPSpm 
was conjugated onto the HNP a decrease in IC50 was achieved. This was particularly 
evident in the case of BxPC-3 cells where a significant (p<0.01) reduction in IC50 
values was observed in both the MTT and trypan blue exclusion assays with an IC50 as 
low as 1.37 µgmL-1 in BxPC-3 cells (Fig. 5A). The increase in activity may be due to 
the internalisation mechanism of the drug. It is hypothesized that the free drug is 
internalised into the cell via a diffusion driven pathway which is time consuming. 
When studying the data of gemcitabine cellular uptake (SI-Fig.5C) the amount of drug 
internalised per cell is greater than that of BNIPSpm. However, even with this 
increased in internalisation, no toxicity was observed.  It is widely reported that the 
majority of nanoparticulate suspensions and colloids are internalised via endocytosis 
[40]. This mechanism of ‘cellular drinking’ is more rapid and the process of engulfing 
and membrane rearrangement results in greater cellular uptake of molecules compared 
to the diffusion mediated routes. Hence, greater internalisation is the likely reason for 
the decreased IC50 of HNP-BNIPSpm (Fig. 5A). The cellular uptake data shown in 
Fig. 5B, confirms this theory, where an increase as high as 8-fold of BNIPSpm in 
BxPC-3 cells was observed after HNP conjugation and 4 h incubation.  
 
In order to gauge the effect of the novel formulation on the immune system, U937 
human monocyte cells were differentiated in order to mimic macrophage like activity. 
Interestingly, greater cellular uptake was observed with the free BNIPSpm compared 
to the HNP bound drug (Fig. 5B). This result is quite surprising as monocyte cells 
typically ‘eat’ and ‘destroy’ any foreign bodies in the bloodstream. Perhaps the 
presence of the poly(ethylene glycol) mimics biological molecules and avoid being 
endocytosed by the cells. More likely however, is that fact that these are a non-
cancerous derived cell line and particularly after differentiation they are not 
proliferating rapidly and hence endocytosis may take longer. Hence, for U937 cells, 
drugs enter cells preferentially via the diffusion mediated pathways. This is reflected 
in the cytotoxicity data presented in Fig.5A where a significant increase in IC50 was 
observed with HNP-BNIPSpm conjugation.  
 
In order to determine whether reversal of drug binding resulted in toxicity 
enhancement in vitro, trypan blue cell viability counting was carried out after 24 h 
exposure to 50 µgmL-1 of the formulation. The protocol carried out was the same 
except these cells had been incubated at increased temperatures (44 ˚C, 60 ˚C) for 0.5 
h. This exposure duration was deemed sufficient to initiate drug release (Fig. 4) 
without causing any adverse effect to the cells. Indeed, at increased temperatures the 
IC50 values dropped although this was only found to be statistically significant 
(p<0.01) in the case of BxPC-3 cells exposed to 60 ˚C (Fig. 5C). Although, this was 
only a crude experiment and it is not certain if it properly reflects the in vivo behavior 
of these drugs after heat initiated release.  
 
Further investigation into the cellular state was studied after drug/formulation 
exposure using AFM imaging technique. The latter has often been used as an early 
indicator of in vitro fate since detailed cellular morphology can be observed. Figure 
5D-E shows the topography images for all three cell lines undergoing the various 
treatment after 1 h exposure. Strikingly, the cancer cell lines incubated with HNP-
BNIPSpm (Fig.5D5, E5) showed completely different profiles to controls (Fig. 5D1, 
E1) with total cellular rearrangement and breakdown starting to occur even after this 
short time exposure. In common with the cytotoxicity (Fig. 5A) and uptake data (Fig. 
4B), those cells treated with free drug (Fig.5D4, E4) also appeared unhealthy, but to a 
lesser extent. Unsurprisingly, the HNP (Fig.5D2, E2) or the gemcitabine treated cells 
(Fig.5D3, E3) did not look notably different to the control cells (Fig. 5D1, E1), with 
smooth, well defined and communicative surface. The U937 cells (Fig.5F) followed a 
similar trend to their cytotoxicity and uptake data, whereby the cells treated with free 
drug (Fig.5 F4) looked less rounded and smooth compared to the control cells (Fig. 
5F1). In agreement with the cytotoxicity data, those cells treated with HNP alone 
(Fig.5 F2) or gemcitabine (Fig.5 F3) did not look notably different from the control 
cells.  
 
3.6 In vivo evaluation 
The novel formulation (HNP-BNIPSpm) was tested on subcutaneous BxPC-3 
xenograft models on the back flank of Nu/Nu mice to determine its in vivo potential as 
an anticancer agent. Although in vitro studies do give some indication of the in vivo 
fate, often large deviation in response between cell lines and in vivo studies is 
observed. In our study, mice with tumours (approx. 0.1 cm3) were dosed at 3 mgKg-1 
once per week over a 4-week period. In order to exploit the thermo-responsive 
properties of these formulations, laser irradiation was used. Extensive previous studies 
have been carried out in order to optimize the laser treatment duration in order to 
achieve temperatures that are likely to initiate drug release without adverse effects to 
tissue [34,35].  
      
Figure 6 A 1 shows a tumour excised from a control group mouse. Unfortunately, the 
mice from this group and the HNP alone group, did not complete the duration of the 
study. This is because their tumour volumes reached the maximum humane limit (0.9 
cm3) and hence the study had to be halted early. Looking at the tumour images (Fig.6 
A) in conjunction with weight (Fig.6 B) and volume (Fig.6 C) data it is evident that no 
reduction in tumour size was observed (Fig.6 A 3 & 4) for the HNP treatment and 
control group. However, those mice treated with BNIPSpm resulted in a significant 
tumour retardation (Fig.6 A 5 & 6). Looking across the control, HNP and BNIPSpm 
groups, no significant (p>0.01) reduction in tumour weight or volume was observed 
due to laser irradiation (Fig.6 2, 4 & 6). Mice treated with HNP-BNIPSpm with no 
laser irradiation (Fig.6 A7) experienced tumour retardation to a slightly lesser extent 
than for those treated with the free drug (Fig.6 A 5), however, this was not deemed to 
be significant (p=0.234). Most excitingly, the HNP-BNIPSpm treated mice which 
underwent laser irradiation experienced a significant enhancement (p<0.01) in tumour 
retardation (Fig.6 A8) compared to the free drug groups. Here, 50% reduction in 
tumour weight (Fig.6B) and volume (Fig. 6C) were experienced. It is estimated that 
the control and HNP group tumours would have reached approximately 1 cm3 by the 
end of the study period had they been allowed to mature. Hence our heat triggered 
system would have resulted in a staggering 5-fold reduction in tumour size.   
 
Ideally, HNP-BNIPSpm without laser irradiation would not result in any tumour 
retardation for the clinical translation to occur. Hence, we postulate that surface 
modification using polymers to wrap the drugs onto the HNP surface until laser 
irradiation and subsequent release will improve their biocompatibility and reduce this 
observed toxicity. Work is underway in our laboratories in order to develop these 
second-generation systems. 
 
4. Conclusion 
This study realises the potential of HNPs as vehicles for heat triggered drug delivery in 
pancreatic cancer therapy. In general, loading capacity of drugs was affected by a 
number of factors including initial drug feeding concentration, the extent of cationic 
charge (number of amino groups in the drug backbone), the presence of sulfur in the 
drug and the type of interaction between drug and HNPs (electrostatic or covalent). 
Our findings show that increasing the number of charges in the polyamine backbone 
leads to stronger electrostatic interaction with the gold surface of the HNP. BNIPSpm 
possessed favourable binding, which was reversible at 44°C. This means the drug 
could be released by heat stimulation via irradiation at the SPR in vivo. The possibility 
of using these systems clinically is not limited to the novel bisnaphthalimide 
compounds. Indeed, any charged drug molecule which exhibits desirable binding and 
uncoupling characteristics could be delivered by this route. Additionally, active 
transport mechanisms for precision targeting could be exploited using specific ligands. 
Undoubtedly the surface chemistry is only limited by area and competition for binding 
sites. Exploitation of these systems for heat triggered drug delivery in combination 
with their imaging capability makes them suitable as theranostic agents.  
 
The advantage of such systems is the ability to treat patients as soon as diagnosis is 
confirmed with more effective and targeting systems which results in reduction in the 
dosage required of these harsh cytotoxic agents in order to observe therapeutic effect, 
reduction in patient side effects and improved long-term outcome. In order for these 
systems to truly be classed as theranostics they must be completely biocompatible 
after drug conjugation until the point of laser initiated drug release. Hence, our lab are 
currently working on the next generation of these systems with careful attention to the 
surface chemistry and immunological response pushing this potential treatment further 
along the pipeline in order to create significant advancement in the treatment of 
pancreatic cancer which could be translated to other cancers. 
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Figures  
Figure 1. A) Schematic representation of drug dissociation from hybrid nanoparticle surface 
after laser irradiation induced heating leading to reversal of electrostatic binding. B) 
Chemical structures of bisnaphthalimido based drugs of varied charge used for binding onto 
hybrid nanoparticle surface: 1. BNIPDi, 2. BNIPd, 3. BNIPSpm & 4. BNIPds. 
 
Figure 2. The synthetic strategy adopted to synthesise new bisnaphthalimides 2-4. 
 
Figure 3. Physical properties of HNPs including A) ability to electrostatically bind 
charged drug molecules onto the surface, B) zeta potential measurement before and 
after drug conjugation and stability of formulations stored at C) 25 °C and D) 4 °C 
(n=3, ±SE).  
 
Figure 4. In vitro drug release of BNIPSpm formulations A) in aqueous solution B) in 
physiological media at 37 °C (red) and 44 °C (blue) (n=3, ±SE). * denotes 
significance compared with all other temperatures tested (p<0.01). 
 
Figure 5. In vitro cellular evaluation on BxPC-3, Panc-1 and U937 cells. A) 
Cytotoxicity assays, B) cellular uptake study, C) thermally initiated cytotoxicity assay 
and D) AFM topography images using Scan Asyst in air mode on fixed 1) control 
cells, and cells incubated with 2) HNPs, 3) gemcitabine 4) BNIPSpm and 5) HNP-
BNIPSpm for 1 h. (n=3±SE). * denotes significance compared to free drug, # denotes 
significance compared to other temperatures tested (p<0.01). 
 
Figure 6. In vivo evaluation on BxPC-3 xenograft models in Nu/Nu 4-6 week old female mice 
dosed once a week at 3 mgKg-1 over 4 weeks. A) Comparison of tumours after excision: 1) 
control, 2) control with laser irradiation, 3) HNP, 4) HNP with laser irradiation, 5) 
BNIPSpm, 6) BNIPSpm with laser irradiation, 7) HNP-BNIPSpm, 8) HNP-BNIPSpm with 
laser irradiation. Solid line: no laser irradiation, dashed line: laser irradiation. Where laser 
irradiation was required this was carried out 24 h after dosing under anaesthetic. The 
tumour was irradiated at 1064 nm as for 20 sec using a ML-LASER-YB5 Q-switched Nd:YAG 
Laser Treatment System. Pulse width: 10 ns, pulse repetition frequency: 6 Hz, laser spot 
diameter: 3 mm, cooling system: water cooled with airflow cooling. The beam was collimated 
through concave lenses to a 1 mm diameter. B) Comparison of tumour weight after excision 
and C) comparison of tumour volume over study duration, n=5±SE). ∞ Study stopped before 
completion due to tumour volume approaching maximum humane volume (0.9 cm3). * 
denotes significance compared to controls, # denotes significance compared to free drug, ∡ 
denotes significance compared to HNP-BNIPSpm without laser irradiation. 
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